ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1136

Urate-Lowering Treatment and Risk of Total Joint Replacement in Patients with Incident Gout: A Population-Based Cohort and Nested Case-Control Study

Jung-Sheng Chen, Chang-Fu Kuo, Ping-Han Tsai, Shue-Fen Luo and Kuang-Hui Yu, Division of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Taoyuan, Taiwan

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Gout and total joint replacement

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 6, 2017

Title: Metabolic and Crystal Arthropathies Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

This cohort study aimed to investigate the risk of total joint (hip/knee) replacement (TJR, THR and TKR) among patients with incident gout at initial diagnosis and subsequent periods. Furthermore, we estimate the exposure dose of urate-lowering treatment (ULT) on the TJR risk by using a nested case-control study.

Methods:

An incident gout cohort during 1995 to 2009 was retrieved from the UK Clinical Practice Research Datalink (CPRD) and were age-, sex and general practice-matched in a 1:4 ratio to controls. Multivariate odds ratios (ORs) for TJR at diagnosis and hazard ratios (HRs) for TJR after diagnosis were estimated adjusting for age, gender, Charlson comorbidity index, BMI level, smoking status, alcohol consumption and comorbidities. Adjusted ORs derived from conditional logistic regression were used to estimate the association between cumulative defined daily dose (cDDD) of urate-lowering treatment and TJR using a nested case-control design.

Results:

There were 40,160 incident gout patients diagnosed during study period and matched to 160,640 controls. Gout was associated with adjusted ORs (95% CIs) of 1.34 (1.15–1.57) for THR and 1.24 (1.02–1.51) for TKR at diagnosis. The incidence of both were higher in gout patients compared with their corresponding controls (3.72 vs 2.47 cases/1000 person-years for THR and 3.57 vs 2.31 cases/1000 person-years for TKR). Multivariate HRs (95% CIs) were 1.22 (1.10–1.35) for THR, 1.09 (0.99–1.21) for TKR and 1.14 (1.06-1.23) for TJR. Using a nested case-control study with gout cohort, ORs (95% CI) for TJR was 1.00 (0.83–1.20) for 1–180 cDDD of ULT, 1.03 (0.80–1.33) for 180–364 cDDD and 1.09 (0.94–1.27) for >365 cDDD compared with non-ULT user.

Conclusion:

Gout was associated with a higher risk of TJR at diagnosis and the risk continue to rise afterwards. TJR risk was not modified by ULT use after gout diagnosis.


Disclosure: J. S. Chen, None; C. F. Kuo, None; P. H. Tsai, None; S. F. Luo, None; K. H. Yu, None.

To cite this abstract in AMA style:

Chen JS, Kuo CF, Tsai PH, Luo SF, Yu KH. Urate-Lowering Treatment and Risk of Total Joint Replacement in Patients with Incident Gout: A Population-Based Cohort and Nested Case-Control Study [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/urate-lowering-treatment-and-risk-of-total-joint-replacement-in-patients-with-incident-gout-a-population-based-cohort-and-nested-case-control-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/urate-lowering-treatment-and-risk-of-total-joint-replacement-in-patients-with-incident-gout-a-population-based-cohort-and-nested-case-control-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology